R&D News In Brief: Otezla Disappoints But Dupilumab Doesn’t, Astellas Files Antifungal And NovoSeven Adds Indication
Executive Summary
POSTURE study will continue unchanged for Celgene’s PDE-4 inhibitor due to meaningful efficacy seen in a pre-specified subgroup with early-stage disease. Astellas submits an NDA for broad-spectrum antifungal isavuconazole in invasive aspergillosis and invasive mucormycosis. Other drug development news, in brief …